Locally advanced non-small cell lung cancer is a heterogeneous group of tumors that require multidisciplinary treatment. Although there is much debate with regard to their management, a multimodal treatment strategy for carefully selected patients that includes surgery can extend survival compared with nonoperative definitive therapy. As the role of targeted therapies and immune checkpoint inhibitors for these tumors becomes better defined, practices will continue to evolve.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2020.07.001 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!